Results 21 to 30 of about 38,595 (290)

Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study. [PDF]

Diabetes Obes Metab
Aims: Type 2 diabetes (T2D) is a heterogeneous disease, with varying pathogenetic mechanisms influencing treatment response. Glucagon-like peptide-1 receptor agonists (GLP-1RA) offer clear metabolic benefits in T2D, but interindividual variability in ...
Caruso I, Giordano F, Matichecchia II, Di Gioia L, Di Molfetta S, Cignarelli A, Sorice GP, Natalicchio A, Laviola L, Giorgino F.   +9 more
europepmc   +2 more sources

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Cardiovascular Diabetology, 2020
Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice.
Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo   +3 more
doaj   +1 more source

Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study. [PDF]

Diabetes Metab Syndr Obes
Binbin Fang,1,* Fen Liu,1,* Junyi Luo,2 Ning Song,2 Chang Liu,2 Wei Ji,2 Xin An,2 Qian Xie,2 Yining Yang,3 Xiaomei Li2 1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical ...
Fang B, Liu F, Luo J, Song N, Liu C, Ji W, An X, Xie Q, Yang Y, Li X.   +9 more
europepmc   +2 more sources

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Cardiovascular Diabetology, 2022
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2
Dario Giugliano, Miriam Longo, Simona Signoriello, Maria Ida Maiorino, Bruno Solerte, Paolo Chiodini, Katherine Esposito   +6 more
doaj   +1 more source

Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care

, 2021
Aims: We evaluated de-intensification of basal-bolus insulin (BBI) after initiation of a GLP-1 receptor agonist (GLP-1RA) under routine care. Research Design and Methods: This retrospective, multicenter study conducted at outpatient clinics in North-East
D'Ambrosio M., Rigato M., Frison V., Tadiotto F., Bonora B. M., Fadini G. P., Avogaro A., Lapolla A., Simioni N., Paccagnella A.   +9 more
core   +1 more source

Hypoglycemia Reporting in GLP-1RA Trials for Type 1 Diabetes: A Critical Gap That Needs To Be Addressed. [PDF]

Endocrinol Diabetes Metab
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Ishtiaq S, Malik ZM, Ahmad AR.
europepmc   +2 more sources

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Military Medical Research, 2022
Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong   +3 more
openaire   +3 more sources

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

Frontiers in Endocrinology, 2022
BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease ...
Cao Li, Shanshan Guo, Jiping Huo, Yiming Gao, Yiming Gao, Yilong Yan, Yilong Yan, Zhigang Zhao   +7 more
doaj   +1 more source

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway

Journal of Diabetes Research, 2022
Background. GLP-1 receptor agonists (GLP-1RA) are common clinical agents that are clinically protective against diabetic complications, such as diabetic retinopathy (DR).
Liufeng Wei, Weiwei Mo, Shanshan Lan, Haiyan Yang, Zhenxing Huang, Xinghuan Liang, Li Li, Jing Xian, Xuemei Xie, Yingfen Qin, Faquan Lin, Zuojie Luo   +11 more
doaj   +1 more source

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice [PDF]

, 2022
Dual agonists activating the peroxisome proliferator-activated receptors alpha and gamma (PPARɑ/ɣ) have beneficial effects on glucose and lipid metabolism in patients with type 2 diabetes, but their development was discontinued due to potential adverse ...
Harger, Alex, DiMarchi, Richard D., Perez-Tilve, Diego, Krahmer, Natalie, Novikoff, Aaron, Klingelhuber, Felix, Herzig, Stephan, Liskiewicz, Arek, Liskiewicz, Daniela, Collden, Gustav, Müller, Timo D., Quarta, Carmelo, KRAHMER, Nathalie, Campbell, Jonathan E., DuBois, Barent, Drucker, Daniel J., Garcia-Caceres, Cristina, Clemmensen, Christoffer, Stemmer, Kerstin, Baugé, Eric, Lalloyer, Fanny, Sanchez-Garrido, Miguel A., Knerr, Patrick J., Hennuyer, Nathalie, Prakash, Sneha, Zhang, Qian, Tschöp, Matthias H., Hofmann, Susanna M., Cota, Perla, Maity, Gandhari, Staels, Bart, Bakhti, Mostafa, Bastidas-Ponce, Aimee, Feuchtinger, Annette, Kulaj, Konxhe, Lickert, Heiko, Capozzi, Megan, Douros, Jon, Finan, Brian, Yang, Bin, Grandl, Gerald   +40 more
core   +2 more sources